Status:
COMPLETED
A Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia
Lead Sponsor:
South China Children's Leukemia Group
Conditions:
Childhood Acute Promyelocytic Leukemia
Eligibility:
All Genders
Up to 16 years
Phase:
PHASE4
Brief Summary
Outcome of acute promyelocytic leukemia (APL) has greatly improved since the introduction of all-trans-retinoic acid (ATRA). Treatment with ATRA and anthracycline-based chemotherapy (ATRA + chemothera...
Detailed Description
OBJECTIVES: * Determine the safety and efficacy of "ATO/RIF + ATRA + less intensive chemotherapy" protocol in children with acute promyelocytic leukemia (APL). * Compare the safety，efficacy and treat...
Eligibility Criteria
Inclusion
- Patients less than 16 years old with newly diagnosed PML-RARa positive acute promyelocytic leukemia.
Exclusion
- Patients who have coma, convulsion or paralysis due to intracranial hemorrhage or central nervous system leukemia at diagnosis.
Key Trial Info
Start Date :
September 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2021
Estimated Enrollment :
176 Patients enrolled
Trial Details
Trial ID
NCT02200978
Start Date
September 1 2011
End Date
October 1 2021
Last Update
May 10 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital of Sun Yat-Sen University
Guangzhou, Guangdong, China, 510080